Kevan C. Herold, MD, C.N.H. Long Professor of Immunology and professor of medicine (endocrinology) at Yale School of Medicine, was recently appointed TrialNet Chair, succeeding Carla J. Greenbaum, MD, who served six years in the position.

New TrialNet research findings published today in Science Translational Medicine show that a 14-day course of the immunotherapy drug teplizumab provided an additional year of delay in onset of type 1 diabetes and improved insulin production, increasing the overall benefit to high-risk individuals reported in the original study fin